Regenerative therapies

Question 1

describe the experiment that showed antiNogoA antibodies to increase axon regeneration in rat spinal cord injury

Answer 1

A T lesion was created in a rodent spinal cord (the dorsal cord and the central part of the ventral cord is injured)
AntiNogoA was intrathecally administered (two diff versions were tested)
it was foudn that there was more growth in the lesion centre when the antibodies were applied
even further away from the centre there was still growth (up to 5mm)
Anti-Nogo A antibodies increase functional recovery and sprouting in non-human primate SCI
Currently in phase II clinical trials – SCI; Phase I – MS

Anti-Nogo A antibodies increase functional recovery and sprouting in non-human primate SCI
Currently in phase II clinical trials – SCI; Phase I – MS

Question 2

what is the furture outlook for myeline derived inhibition

Answer 2

Knockout mice don’t show as favourable repair as antibodies.
* NogoA knockouts have produced variable amounts of axon regeneration after injury.
* One knockout regenerates vigorously
* One regenerates a bit
* One doesn’t regenerate at all.
* This means that for clinical trials its unknown – it is a viable treatment but obviously not certainty
A triple knockout of NogoA, MAG, OMgp shows no regeneration after injury.
Suggests that transgenic regulate these proteins differently